The development and evaluation of a questionnaire to assess the impact of vulval intraepithelial neoplasia: a questionnaire study

2013 ◽  
Vol 120 (9) ◽  
pp. 1133-1143 ◽  
Author(s):  
J Lockhart ◽  
NM Gray ◽  
ME Cruickshank
Keyword(s):  
Intraepithelial Neoplasia ◽  
Questionnaire Study ◽  
Vulval Intraepithelial Neoplasia ◽  
The Impact

scholarly journals Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses

2021 ◽  
Author(s):  
Alejandra Castanon ◽  
Matejka Rebolj ◽  
Francesca Pesola ◽  
Peter Sasieni
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Intraepithelial Neoplasia ◽  
Cervical Cancers ◽  
Screening Interval ◽  
Recovery Strategies ◽  
Screening Services ◽  
The Impact ◽  
Published Research

Abstract Background The COVID-19 pandemic has disrupted cervical cancer screening services. Assuming increases to screening capacity are unrealistic, we propose two recovery strategies: one extends the screening interval by 6 months for all and the other extends the interval by 36/60 months, but only for women who have already missed being screened. Methods Using routine statistics from England we estimate the number of women affected by delays to screening. We used published research to estimate the proportion of screening age women with high-grade cervical intraepithelial neoplasia and progression rates to cancer. Under two recovery scenarios, we estimate the impact of COVID-19 on cervical cancer over one screening cycle (3 years at ages 25–49 and 5 years at ages 50–64 years). The duration of disruption in both scenarios is 6 months. In the first scenario, 10.7 million women have their screening interval extended by 6 months. In the second, 1.5 million women (those due to be screened during the disruption) miss one screening cycle, but most women have no delay. Results Both scenarios result in similar numbers of excess cervical cancers: 630 vs. 632 (both 4.3 per 100,000 women in the population). However, the scenario in which some women miss one screening cycle creates inequalities—they would have much higher rates of excess cancer: 41.5 per 100,000 delayed for screened women compared to those with a 6-month delay (5.9 per 100,000). Conclusion To ensure equity for those affected by COVID-19 related screening delays additional screening capacity will need to be paired with prioritising the screening of overdue women.

scholarly journals Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 410
Author(s):  
Violante Di Donato ◽  
Giuseppe Caruso ◽  
Marco Petrillo ◽  
Evangelos Kontopantelis ◽  
Innocenza Palaia ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Meta Analysis ◽  
Hpv Vaccination ◽  
Cervical Dysplasia ◽  
Reduction Rate ◽  
Intraepithelial Neoplasia ◽  
Surgical Excision ◽  
Inclusion Criteria ◽  
Mean Differences ◽  
The Impact

Objective: The aim of this meta-analysis was to discuss evidence supporting the efficacy of adjuvant human papillomavirus (HPV) vaccination in reducing the risk of recurrent cervical intraepithelial neoplasia (CIN) 2 or greater after surgical treatment. Methods: A systematic literature search was performed for studies reporting the impact of HPV vaccination on reducing the risk of recurrence of CIN 2+ after surgical excision. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Results: Eleven studies met the inclusion criteria and were selected for analysis. In total, 21,310 patients were included: 4039 (19%) received peri-operational adjuvant HPV vaccination while 17,271 (81%) received surgery alone. The recurrence of CIN 2+ after treatment was significantly lower in the vaccinated compared with the unvaccinated group (OR 0.35; 95% CI 0.21–0.56; p < 0.0001). The recurrence of CIN 1+ after treatment was significantly lower in the vaccinated compared with the unvaccinated group (OR 0.51; 95% CI 0.31–0.83; p = 0.006). A non-significant trend of reduction rate of HPV persistence was observed in the vaccinated compared with the unvaccinated cohorts (OR was 0.84; 95% CI 0.61–1.15; p = 0.28). Conclusions: HPV vaccination, in adjuvant setting, is associated with a reduced risk of recurrent CIN 1+ and CIN 2+ after surgical treatment.

scholarly journals Variability of Pathologists' Utilization of p16 and Ki-67 Immunostaining in the Diagnosis of Cervical Biopsies in Routine Pathology Practice and Its Impact on the Frequencies of Cervical Intraepithelial Neoplasia Diagnoses and Cytohistologic Correlations

2014 ◽  
Vol 138 (1) ◽  
pp. 76-87 ◽  
Author(s):  
Charanjeet Singh ◽  
J. Carlos Manivel ◽  
Alexander M. Truskinovsky ◽  
Kay Savik ◽  
Samy Amirouche ◽  
...  
Keyword(s):  
Cervical Intraepithelial Neoplasia ◽  
Intraepithelial Neoplasia ◽  
Lower Range ◽  
Ki 67 ◽  
Detection Rates ◽  
Cervical Biopsy ◽  
Biopsy Specimens ◽  
Frequency Of Use ◽  
Lower Variability ◽  
The Impact

Context.—The use of p16 in cervical biopsies improves the accuracy of cervical intraepithelial neoplasia (CIN) diagnosis and grading and decreases its interpathologist variability. Objective.—To determine the impact of the frequency of use of p16 immunostains in cervical biopsies on pathologists' diagnoses of CIN grade 1 and grade 2 or above (CIN1 and CIN2+) and on cytohistologic correlations. Design.—We identified all cervical biopsy specimens with cytologic correlations subjected or not to p16 staining from January 1, 2005, to September 30, 2010; calculated each pathologist's percentage of p16 use; and correlated it with their major cytohistologic discrepancy rates, CIN2+ diagnoses, and CIN1/CIN2+ ratios. Results.—During the study period, each of the 23 pathologists interpreted 59 to 1811 (mean, 518) of 11 850 cervical biopsy specimens, used p16 for 0% to 21.31% (mean, 10.14%) of these, had CIN2+ detection rates of 9.5% to 24.1% (mean, 18.9%), and CIN1/CIN2+ ratios of 0.7 to 4.5 (mean, 1.5). Compared to the 12 “low users” of p16, who used p16 fewer times than the institution's mean for p16 use, the 11 “high users” of p16 diagnosed more biopsies (8391 versus 3459), had a lower rate of major cytohistologic discrepancies (12.62% versus 14.92%, P &lt; .001), a higher rate of CIN2+ diagnoses (19.9% versus 16.4%, P &lt; .001), a lower range of CIN2+ rates (15.0%–23.1% versus 9.5%–24.1%), and lower CIN1/CIN2+ ratios (1.2 versus 2.3). Conclusions.—We found a high intrainstitutional variability of p16 use in cervical biopsies, CIN2+ rates, and CIN1/CIN2+ ratios. Use of p16 for greater than 10% of cervical biopsies was associated with improved cytohistologic correlation rates and with lower variability in the frequencies of histologic diagnoses.

The Impact of ISTCS – A Clinician's Perspective (Questionnaire Study)

2010 ◽  
Vol 92 (9) ◽  
pp. 1-3
Author(s):  
D Mendis ◽  
A Hawrani
Keyword(s):  
Healthcare Delivery ◽  
Postal Questionnaire ◽  
Questionnaire Study ◽  
Case Mix ◽  
Day Case ◽  
General Attitude ◽  
Inpatient Services ◽  
The Impact ◽  
Training Opportunities ◽  
Controversial Aspect

Independent sector treatment centres and their effect on the NHS remain a controversial aspect of healthcare delivery. This postal questionnaire study aims to identify the general attitude among surgical consultants about their effects, specifically on NHS workload, departmental/trust finances, training opportunities and case mix. NHS hospitals within five miles of an ISTC offering day case/inpatient services were targeted.

Sign in / Sign up

Export Citation Format

Share Document